SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01705639

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?

The effect of 3 months of melatonin 4mg treatment on glucose tolerance in different variants of the melatonin receptor 1B gene will be evaluated. The following will be done at 0 and 3 months: - OGTT - questionnaires about sleep and activity - Actigraph - Anthropometry - Blood pressure

NCT01705639 Diabetes Glucose Tolerance

1 Interventions

Name: Melatonin

Description: All subjects receive the same dose of melatonin

Type: Drug

Melatonin


Primary Outcomes

Description: Glucose tolerance is measured in OGTT: 0,30,60,90 and 120 minute values of glucose and insulin.

Measure: Glucose tolerance

Time: 3 months

Secondary Outcomes

Description: monitoring of sleep with questionnaires and activity monitoring

Measure: sleep

Time: 3 months

Description: Activity and sleep of the subjects is recorded with Actigraph at 0 and 3 months

Measure: Activity

Time: 3 months

Purpose: Basic Science

Single Group Assignment


There is one SNP

SNPs


1 rs10830963

Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?. Melatonin and Glucose Tolerance Among Individuals With a Variant of the MTNR1B Gene The effect of 3 months of melatonin 4mg treatment on glucose tolerance in different variants of the melatonin receptor 1B gene will be evaluated.



HPO Nodes